/
SEER
$1.66+$0.00 (+0.00%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$91.3M
55M shares
52-week range
$1.65 – $2.41
1% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
0.49%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-29.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $116.0K | $656.0K | $6.4M | $14.7M | $15.2M | $13.9M | $16.1M |
| Cost of revenue | $100.0K | $701.0K | $1.6M | $6.8M | $14.3M | $13.7M | $7.1M | $8.1M |
| Gross profit | −$100.0K | −$585.0K | −$950.0K | −$374.0K | $384.0K | $1.4M | $6.8M | $8.0M |
| Gross margin | — | -504.3% | -144.8% | -5.8% | 2.6% | 9.5% | 49.0% | 49.7% |
| R&D | $3.7M | $11.7M | $17.3M | $29.1M | $45.8M | $47.4M | $50.6M | $43.9M |
| Operating income | −$6.8M | −$16.9M | −$33.6M | −$71.7M | −$98.0M | −$104.9M | −$100.1M | −$78.0M |
| EBITDA | −$6.2M | −$15.3M | −$31.2M | −$67.6M | −$87.1M | −$80.7M | −$80.3M | −$71.9M |
| Net income | −$6.3M | −$16.0M | −$32.8M | −$71.2M | −$93.0M | −$86.3M | −$86.6M | −$73.6M |
| Net margin | — | -13825.9% | -4996.2% | -1113.1% | -633.1% | -568.3% | -620.9% | -456.6% |
| EPS (diluted) | -0.29 | -0.26 | -0.51 | -1.13 | -1.42 | -1.35 | -1.39 | -1.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-0.82 | $-0.83–$-0.82 | 1 |
| 2027 | $21M | $-0.73 | $-0.77–$-0.69 | 1 |
| 2028 | $28M | $-0.65 | $-0.66–$-0.64 | 1 |
| 2029 | $36M | $-0.55 | $-0.55–$-0.54 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Seer, Inc. Class A Common Stock
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
www.seer.bio- Employees
- 124
- IPO / List date
- Dec 4, 2020
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds SEER.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 976,688 | $1.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SEER yet.
